中國Examination GuidePatent Lawprosecutionutility models
2022年11月24日

China Proposes New Examination Guidelines for Utility Models

by
張佩雯女士
王怡瑾女士
車李曉芸女士

The Utility Model (UM) in China has always been a popular choice for patent filing due to its relatively low cost and speed of prosecution. The UM prosecution only includes a preliminary examination, which is essentially a mini (stripped down) version of an invention application’s substantive examination.1 With the simplified examination process, UMs are typically granted without issue. Unfortunately, this may soon not be the case anymore.

Heightened Inventiveness Standard + Formal Search

The CNIPA2 has recently published an official letter in response to a Proposal from a CPPCC member regarding problematic patents and malicious competition based thereon in the lithium battery industry.34 The key messages stated in these letters is that the CNIPA is preparing a draft amendment to the Implementing Regulations and Examination Guidelines,5 emphasizing that “obviously lack of inventiveness” will be incorporated into the scope of a UM’s preliminary examination, and that the goal of such prospective change is to optimize the examination standards and the quality of granted patents in China.

Unsurprisingly, the change for UMs mentioned in the above letters was proposed a while ago. According to the proposed amendment to the Examination Guidelines published last year and recently,67 it appears that the scope of the preliminary examination for UMs will be significantly expanded to include an examination for inventiveness and a formal prior art search. This will likely cause an increase in prosecution time due to the more throughout examination as well as more challenging office actions. Further, procedures that used to be exclusive to invention applications, such as deferral of substantive examination and patent term adjustment, will also become available for UM applications, with one catch: for same-day applications,8 if the UM has been granted, the subsequently granted invention will not be eligible for patent term adjustment.

As such, the benefits of same-day application will potentially become less prominent compared to the current state, especially for UMs having small improvements over the prior art, although it is hard to say for sure right now, as it is not yet clear how the “obviously lacking inventiveness” standard will apply.

The Value of Utility Model Applications

Nonetheless, we don’t think that UMs will lose their value entirely. At least for now, the value of UMs for marketing purposes and/or to meet certain government or university requirements still exists. Despite any potential prosecution time increase, we think UMs still have business benefits that can outweigh the cost incurred during prosecution and maintenance.

Furthermore, more in-depth examination for all UMs will help minimize the number of problematic patents overall, ensuring fair competition among patent owners in China. As you can imagine, in actual practice there are often discrepancies between different examiners when deciding whether a UM is allowable. Historically, changes in examination guidelines have forced examiners to readjust their practice, ultimately leading to more unified examination standards across the board.

While this new inventiveness standard is likely challenging for UM inventions having very subtle improvements, we expect more sophisticated UMs will benefit from a more unified (and thus more “fair”) examination standard. We look forward to seeing how this updated change will work out in practice over time.

More proposed amendments to the Examination Guidelines are underway this year. We will continue to monitor the status of the new proposed amendments and keep you updated on further developments. Stay tuned!

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

  1. During the examination, the current practice is that examiners will determine whether the UM is obviously lacking novelty or practical applicability, according to Article 22.2 or 22.4 of the Patent Law, respectively, but not inventiveness. ↩︎
  2. China National Intellectual Property Administration, the Chinese patent office ↩︎
  3. Letter of the State Intellectual Property Office in Response to the Recommendation No. 8842 of the Fifth Session of the Thirteenth National People’s Congress, 20 Jul 2022, https://www.cnipa.gov.cn/art/2022/7/22/art_516_176743.html ↩︎
  4. Letter of the State Intellectual Property Office in Response to the Proposal No. 03510 (No. 160 of Science and Technology) of the Fifth Session of the Thirteenth National Committee of the Chinese People’s Political Consultative Conference, 29 Aug 2022, https://www.cnipa.gov.cn/art/2022/9/6/art_516_178500.html ↩︎
  5. Guidelines for Patent Examination (2021) and Implementing Regulations of the Patent Law ↩︎
  6. Appendix 1, Part I, Chapter 2.11, Notice on Revised Guidelines for Patent Examination (First Draft for Comments) (Published 3 Aug 2021), https://www.cnipa.gov.cn/art/2021/8/3/art_75_166474.html ↩︎
  7. Appendix 1, Part 5, Chapter 7.8.3, Notice on Revised Guidelines for Patent Examination (Second Draft for Comments) (Published 31 Oct 2022), https://www.cnipa.gov.cn/art/2022/10/31/art_75_180016.html ↩︎
  8. Chinese invention and utility model applications filed on the same day. For more information, see this article. ↩︎

其他文章

New Fee Standards Released for Chinese Patent Applications

2024年9月6日
Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE). Please find our summary below: PCT application fee deduction rules   Application fee & extra […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

How Smart is a "Skilled Person in the Art"?

2022年4月11日
Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

2021年4月30日
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

我們過去活動

Top crossarrow-right